Review Article
Effectiveness and Safety of Compound Chinese Medicine plus Routine Western Medicine in In-Stent Restenosis: A Meta-Analysis and Systematic Review
Table 5
Subgroup analysis of CCM plus RWM versus RWM in cases of ISR.
| | RWM | Studies | RR (95% CI) | |
| | DAPT | 4 | 0.32 [0.18, 0.57] | 0% | | DAPT + Statin | 13 | 0.45 [0.32, 0.64] | 0% | | DAPT + β-blocker + Statin | 4 | 0.36 [0.20, 0.64] | 0% | | DAPT + ACEI/ARB + Statin + Metformin | 1 | | | | Nitrates + DAPT + Statin | 2 | 0.36 [0.12, 1.08] | 0% | | Nitrates + DAPT + ACEI/ARB + Statin | 1 | | | | Nitrates + DAPT + β-blocker + Statin | 2 | 0.58 [0.24, 1.42] | 0% | | Nitrates + DAPT + ACEI/ARB + β-blocker + Statin | 2 | 0.39 [0.21, 0.70] | 70% | | Nitrates + DAPT + ACEI/ARB + β-blocker + Statin + CCB | 2 | 0.57 [0.37, 0.86] | 0% | | Unclear | 3 | | |
|
|
